| Literature DB >> 27873282 |
Lauren P McLaughlin1,2, Stephen Gottschalk3, Cliona M Rooney4, Catherine M Bollard5,6.
Abstract
Epstein Barr virus (EBV) is a human gamma herpes virus that establishes latency in B cells after primary infection. EBV generally only causes a mild, self-limiting viral illness but is also associated with several malignancies including posttransplantation lymphoproliferative disorder in the immunosuppressed host as well as Hodgkin and non-Hodgkin lymphoma in the immune competent host. The expression of EBV antigens by lymphoma has important applications as targets for adoptive T cell therapy. However, as many lymphomas only express subdominant EBV antigens that are less immunogenic, novel strategies are needed to manufacture EBV-specific T cell products specific for Latent Membrane Protein 1 (LMP1) and LMP2, which are expressed in lymphomas with type II and III latency. While several techniques for manufacturing EBV-CTLs are described in the literature, this chapter focuses on one method for generating Good Manufacturing Practice (GMP)-compliant EBV-specific T cell products that are enriched with LMP1 and LMP2.Entities:
Keywords: Adoptive T cell therapy; Epstein Barr virus; Good manufacturing practice; Lymphoma
Mesh：
Substances：
Year: 2017 PMID： 27873282 DOI： 10.1007/978-1-4939-6655-4_19
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745